Induction of cross-tolerance by lipopolysaccharide and highly purified lipoteichoic acid via different Toll-like receptors independent of paracrine mediators.
Exposure of macrophages to LPS induces a state of hyporesponsiveness to subsequent stimulation with LPS termed LPS desensitization or tolerance. To date, it is not known whether similar mechanisms of macrophage refractoriness are induced on contact with components of Gram-positive bacteria. In the present study, we demonstrate that pretreatment with highly purified lipoteichoic acid (LTA) results in suppression of cytokine release on restimulation with LTA in vitro and in vivo in both C3H/HeN and C3H/HeJ mice, but not in macrophages from Toll-like receptor (TLR)-2-deficient mice. Furthermore, desensitization in response to LPS or LTA exposure also inhibits responses to the other stimulus ("cross-tolerance"), suggesting that signaling pathways shared by TLR2 and TLR4 are impaired during tolerance. Finally, we show that LPS- or LTA-induced cross-tolerance is not transferred to hyporesponsive cells cocultured with LPS/LTA-responsive macrophages, showing that soluble mediators do not suffice for tolerance induction in neighboring cells.
Lehner
M D
MD
Biochemical Pharmacology, University of Konstanz, Konstanz, Germany.
Morath
S
S
Michelsen
K S
KS
Schumann
R R
RR
Hartung
T
T
D000818:Animals; D002478:Cells, Cultured; D018920:Coculture Techniques; D029721:Drosophila Proteins; D005260:Female; D007108:Immune Tolerance / Q000235:genetics; D018836:Inflammation Mediators / Q000502:physiology*; D007274:Injections, Intraperitoneal; D007375:Interleukin-1 / Q000502:physiology; D016753:Interleukin-10 / Q000502:physiology; D008070:Lipopolysaccharides / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D017737:Macrophages, Peritoneal / Q000276:immunology / Q000378:metabolism; D008297:Male; D008562:Membrane Glycoproteins / Q000235:genetics / Q000502:physiology*; D051379:Mice; D008809:Mice, Inbred C3H; D018345:Mice, Knockout; D019899:Paracrine Communication / Q000276:immunology; D011956:Receptors, Cell Surface / Q000235:genetics / Q000502:physiology*; D012995:Solubility; D013682:Teichoic Acids / Q000008:administration & dosage / Q000276:immunology* / Q000494:pharmacology; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; D016212:Transforming Growth Factor beta / Q000502:physiology
D029721:Drosophila Proteins; D018836:Inflammation Mediators; D007375:Interleukin-1; D008070:Lipopolysaccharides; D008562:Membrane Glycoproteins; D011956:Receptors, Cell Surface; D013682:Teichoic Acids; D051195:Toll-Like Receptor 2; D051197:Toll-Like Receptor 4; D051193:Toll-Like Receptors; D016212:Transforming Growth Factor beta; D016753:Interleukin-10; C009900:lipoteichoic acid